RT Journal Article
T1 Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
A1 Pajares, Bella
A1 Pollán, Marina
A1 Martín, Miguel
A1 Mackey, John R
A1 Lluch, Ana
A1 Gavila, Joaquín
A1 Vogel, Charles
A1 Ruiz-Borrego, Manuel
A1 Calvo, Lourdes
A1 Pienkowski, Tadeusz
A1 Rodríguez-Lescure, Alvaro
A1 Seguí, Miguel Ángel
A1 Tredan, Olivier
A1 Antón, Antonio
A1 Ramos, Manuel
A1 Cámara, María del Carmen
A1 Rodríguez-Martín, César
A1 Carrasco, Eva
A1 Alba, Emilio
K1 Neoplasias de la Mama
K1 Obesidad
K1 Índice de Masa Corporal
K1 Antineoplásicos
K1 Supervivencia sin Enfermedad
K1 Pronóstico
K1 Femenino
K1 Análisis de Supervivencia
AB INTRODUCTIONObesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification.METHODSWe performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003-02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences of such prognostic effects by subtype.RESULTSMultivariate survival analyses adjusting for age, tumor size, nodal status, menopausal status, surgery type, histological grade, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, chemotherapy regimen, and under-treatment showed that obese patients (BMI 30.0 to 34.9) had similar prognoses to that of patients with a BMI < 25 (reference group) in terms of recurrence (Hazard Ratio [HR] = 1.08, 95% Confidence Interval [CI] = 0.90 to 1.30), BCM (HR = 1.02, 0.81 to 1.29), and OM (HR = 0.97, 0.78 to 1.19). Patients with severe obesity (BMI ≥ 35) had a significantly increased risk of recurrence (HR = 1.26, 1.00 to 1.59, P = 0.048), BCM (HR = 1.32, 1.00 to 1.74, P = 0.050), and OM (HR = 1.35, 1.06 to 1.71, P = 0.016) compared to our reference group. The prognostic effect of severe obesity did not vary by subtype.CONCLUSIONSSeverely obese patients treated with anthracyclines and taxanes present a worse prognosis regarding recurrence, BCM, and OM than patients with BMI < 25. The magnitude of the harmful effect of BMI on survival-related outcomes was similar across subtypes.
PB BioMed Central
SN 1465-5411
YR 2013
FD 2013-11-06
LK http://hdl.handle.net/10668/1446
UL http://hdl.handle.net/10668/1446
LA en
NO Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res.. 2013   ; 15(6):R105
NO JOURNAL ARTICLE;
DS RISalud
RD Apr 12, 2025